World Health Organization (WHO) has identified infectious disease drugs as a priority issue during the COVID-19 pandemic, as well as key structural factors affecting access to non-communicable disease (NCD) drugs. The report highlights the impact of COVID-19 on the global pharmaceutical supply chain, including manufacturing disruptions, export restrictions, and border effects. It also discusses the importance of increasing safety stocks, local production, and improving supply chain governance and transparency. The report emphasizes the need for increased flexibility in payment methods, improved demand response capabilities, and the establishment of reporting mechanisms for shortages and price and supply transparency. The report also highlights the importance of monitoring and reporting on drug shortages, as well as improving access and affordability of NCD drugs.
